EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
